PureTech Health (PRTC) noted that its founded entity, Seaport Therapeutics, announced that the first participant has been dosed in the Phase 1 study of GlyphAgo.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- Buy Rating for PureTech Health Driven by Promising LYT-100 Developments and Strategic Initiatives
- PureTech Health Reports Strong Progress and Financial Stability
- PureTech says Vedanta ulcerative colitis study missed endpoint
- PureTech falls 7% to $16.19 after founded entity study miss
- DiaMedica Therapeutics CMO Lorianne Masuoka resigns, Julie Krop succeeds